TABLE 6.
Hepcidin (ng/mL) levels (full analysis set)
| ESA‐Naïve Studya | ESA‐Converted Studyb | |||
|---|---|---|---|---|
| Roxadustat 50 mg (N = 37) | Roxadustat 70 mg (N = 37) | All ESA‐Naïve (N = 74) | All ESA‐Converted (N = 163) | |
| Baseline | 41.673 (25.296) | 38.015 (22.001) | 39.844 (23.615) | 28.777 (25.142) |
| Week 4 | 13.241 (17.391) | 14.919 (19.206) | 14.080 (18.208) | 19.547 (22.194) |
| EoT | 15.494 (17.315) | 17.797 (17.981) | 16.645 (17.568) | 22.618 (26.449) |
| Change from baseline to EoT | −26.179 (23.383) | −20.218 (22.183) | −23.199 (22.832) | −6.159 (29.026) |
Note: Data are reported as mean (SD).
Abbreviations: EoT, end of treatment; ESA, erythropoiesis‐stimulating agent.
a
The study duration was 24 weeks.
b
The study duration was 52 weeks.